An Update on the Histology of Pheochromocytomas: How Does it Relate to Genetics?

Authors
Lindsey Oudijk1, José Gaal2, Karen Koopman2, Ronald R. de Krijger3

Affiliations
1 Department of Pathology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
2 Department of Pathology, Isala Clinics, Zwolle, The Netherlands
3 Department of Pathology, University Medical Center/Princess Maxima Center for Pediatric Oncology, Utrecht and Reinier de Graaf Hospital, Delft, The Netherlands

Key words
pheochromocytoma, histology, genetics

Bibliography
DOI https://doi.org/10.1055/a-0672-1266
Published online: 24.8.2018
Horm Metab Res 2019; 51: 403–413
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0018-5043

Correspondence
Lindsey Oudijk
Department of Pathology
Erasmus MC University Medical Center

Introduction
Pheochromocytomas (PCC) and paragangliomas (PGL) are rare tumors, originating from neural crest-derived precursor cells, that occur in the adrenal gland and in sympathetic and parasympathetic ganglia in the abdomen, thorax, pelvis, and head and neck area, respectively. Histologically, they are very similar and frequently indistinguishable, although PCC tend to have more nuclear atypia and cytoplasmic basophilia, whereas PGL display less atypia and are usually more eosinophilic. Their histopathological recognition is usually straightforward and in equivocal cases the neuroendocrine markers synaptophysin and chromogranin A can be used, both of which should show diffuse strong cytoplasmic staining. In addition, the use of S100 may be supportive when showing a sustentacular cell pattern of non-neoplastic cells that surround the nodules of PCC tumor cells, the so-called “Zellballen” (Fig. 1).

Over the past decades, it has been shown that these tumors carry a very high rate of germline mutations, up to 35 % to 40 % in some series, making them one of the most heritable tumor types in the body, necessitating clinical genetic counseling and germline mutation analysis in every patient [1, 2]. The number of genes with germline mutations leading to PCC and PGL has increased to almost 20, although for some genes only few families or index patients have been described. While we are entering the era of genome-wide mutation analysis at ever decreasing cost, currently such an approach is not the state of the art in most settings, even in developed countries. Therefore, a stepwise approach, guided by clinical and histopathological information is currently still preferred. This review article describes the various (groups of) germline mutations and the contribution of gross analysis of adrenalectomy specimens, histopathology on the basis of hematoxylin and eosin (HE)-stained sections, and immunohistochemistry to the elucidation of a potential hereditary background of PCC and PGL.
Multiple Endocrine Neoplasia Type 2

Multiple endocrine neoplasia type 2 (MEN2) was first described in 1961. It is a rare autosomal dominant syndrome caused by mutations in the RET proto-oncogene. This gene is located on chromosome 10q11.2 and encodes a transmembrane tyrosine kinase enzyme. When ligand binds to the RET receptor, or if there is an activating mutation, a cell signaling cascade is triggered through the PI3 kinase pathway to regulate cell proliferation and apoptosis [3–5].

MEN2A is the most common subtype of MEN2 and comprises medullary thyroid carcinoma, PCC, and primary hyperparathyroidism. MEN2B is characterized by medullary thyroid cancer, PCC, a Marfanoid habitus, and mucosal ganglioneuromas. PCC occur in 40–50% of patients with MEN2, are usually detected between 30 and 40 years of age, and are the presenting tumor in up to 25% of MEN2 patients. The risk of PCC is associated with specific RET mutations [3, 6]. The rate of metastatic PCC is less than 5% [7]. Clues to a MEN2-related PCC are multiple and bilateral tumor nodules and the presence of adrenal medullary hyperplasia (AMH). In addition, AMH and PCC show identical molecular alterations. This suggests that AMH does not represent a physiologic increase of adrenal medullary cells, but should be regarded as a precursor lesion of PCC or as a small PCC [8–10]. Individual PCC can differ from each other both architecturally and cytologically. Hyaline globules are often abundant in MEN2 [11].

Von Hippel–Lindau

Von Hippel–Lindau (VHL) is an autosomal dominant familial tumor syndrome characterized by multiple benign and malignant tumors including retinal and central nervous system hemangioblastomas, renal cysts and renal clear cell carcinomas, pancreatic cysts and pancreatic neuroendocrine tumors, endolymphatic sac tumors, and epididymal cystadenomas [1]. VHL is categorized into two major types depending on the absence (type 1) or presence of PCC (type 2). Germline mutations in the VHL tumor suppressor gene at chromosome 3p25 in combination with a second hit with loss of the wild type allele result in tumorigenesis. The VHL gene encodes two proteins (pVHL30 and pVHL19). pVHL plays a critical role in regulating the degradation of hypoxia inducible factor (HIF)1alpha and HIF2alpha. HIFs can activate genes that participate in cellular adaptation and growth under hypoxic conditions. Under normal conditions, pVHL can bind to the α subunits of the transcription factors HIF1 and HIF2 and targets them for ubiquitination and proteosomal degradation. Under hypoxic conditions or pVHL dysfunction, HIFs are stabilized and activate target genes inducing angiogenesis, metabolism, apoptosis, and proliferation [12]. Type 1 VHL is usually associated with non-functional protein mutations, whereas in type 2 VHL mutations encode a protein with some activity [4, 12].

PCC are observed in 10–26% of VHL patients, with a mean age of presentation of 30 years and PCC can be the first clinical symptom in one third of the patients. The metastatic rate is 5% [4, 12]. VHL-related PCC are often bilateral and/or multifocal, but in contrast to MEN2 there is no AMH. Other distinctive features of PCC in VHL are a thick vascular tumor capsule, myxoid stroma, small to medium sized tumor cells with prominent amphiphilic and/or clear cytoplasm, intermingling of small vessels, absence of hyaline globules, and lack of nuclear atypia or mitosis [13]. It has been suggested that membranous carbonic anhydrase IX expression (a hypoxia marker) may be a potential immunohistochemical marker for VHL-related PCC, but further validation is required [14].

Neurofibromatosis Type 1

Neurofibromatosis type 1 (NF1), an autosomal dominant disorder, is caused by inactivating mutations in the NF1 gene, located on chromosome 17q11.2. This gene encodes neurofibromin 1, which is a negative regulator of the RAS intracellular signaling pathway. The syndrome is characterized by multiple neurofibromas, café au lait spots, axillary and inguinal freckling, Lisch nodules of the iris, optic nerve gliomas, dysplasia of the long bones, peripheral nerve sheath tumors, gastrointestinal stromal tumors (GIST), pancreatic neuroendocrine tumors, leukemia, and PCC. The diagnosis is based on clinical diagnostic criteria rather than genetic testing since the gene is large and there is no hotspot for mutations [15]. Less than 6% of NF1 patients develop PCC with a mean age of presentation of 42 years. Bilateral tumors are seen in 25% of these patients. The metastatic rate is 12% [3]. Up to 16% of PCC in NF1 show a composite phenotype of PCC intermixed with areas of ganglioneuroblastoma or ganglioneuroma [16]. Immunohistochemical NF1 staining does not predict NF1 gene mutation status in PCC [17].
Succinate Dehydrogenase Enzyme-related Genes

Germline mutations in one of the succinate dehydrogenase (SDH) genes are the most frequent cause of hereditary PCC/PGL and account for nearly 50% of mutations in these tumors [10]. The SDH complex is a key respiratory enzyme for normal aerobic respiration located at the inner mitochondrial membrane [18]. The complex is composed of the four subunits SDHA, SDHB, SDHC, and SDHD, each encoded by corresponding genes on the autosomal DNA [18]. Succinate dehydrogenase assembly factor 2 (SDHAF2) is needed for the flavination and correct functioning of SDHA [19]. If any of the SDH components is lost due to (epi)mutation, the entire complex becomes unstable and the SDHB subunit is degraded in the cytoplasm [18]. The consequent loss of SDHB protein expression can be detected by the use of immunohistochemistry for the SDHB protein [20]. Tumors with inactivation of SDHA, SDHB, SDHC, SDHD, or SDHAF2 do not show specific gross or microscopic characteristics that distinguish them from other PCC. However, they demonstrate loss of cytoplasmic SDHB staining [21]. So, SDHB immunohistochemistry can be used as a quick and cheap marker for syndromic SDH deficient tumors.

In addition, SDHA immunohistochemistry can be used to detect tumors with germline SDHA mutations, as SDHA staining becomes negative in SDHA-mutated tumors, while tumors with SDHB, SDHC, SDHD, or SDHAF2 mutations retain SDHA staining [22]. SDHD immunostaining has been described as an adjunct in cases with difficult to interpret SDHB staining due to nonspecific background [23], as SDHD immunostaining is positive in SDH-mutated cases. However, this has not been validated in other studies.

Interpretation of SDH immunohistochemistry has its pitfalls [24]. To start with, it is very important that an intrinsic positive control is identified in non-tumoral cells, that is, endothelial cells, fibroblasts or immune cells. Then, one should look at the pattern and intensity of staining: normal (mitochondrial) positive staining is strongly granular and cytoplasmic. When the cytoplasmic staining of the tumor cells is clearly less intense compared to the staining of the endothelial cells, SDHB should be considered negative. Also, when there is a weak diffuse cytoplasmic blush instead of a strong granular pattern, SDHB should be regarded as negative (Fig. 2d). The latter scenario is more likely to occur in SDH-mutated tumors [23]. Also, caution should be taken when interpreting SDHB immunohistochemistry in tumor areas with clear cytoplasm, as staining might occur negative. The best approach is to look for (focal) areas with eosinophilic cytoplasm to interpret the staining [25].

Syndromic PCC/PGL with germline SDH mutations show clinicopathological associations that must be borne in mind by both clinicians and pathologists. In short, SDHB-mutated tumors are mainly extra-adrenal sympathetic PGL and are associated with a high risk of metastasis [26–28]. Germline SDHD mutations predispose most frequently to multiple non-metastatic head and neck PGL [28]. SDH mutations are rare and are mainly associated with carotid body PGL [28]. Both SDHD and SDHAF2 are maternally imprinted and disease only develops after paternal transmission [29, 30]. SDHA mutations are extremely rare and display a reduced penetrance [31]. Most importantly, there are newly recognized SDH-associated tumors, such as GIST, renal cell carcinomas (RCC) and pituitary adenomas (PA), which will briefly be discussed hereafter.

SDH-deficient GIST show distinct clinical, morphological and immunohistochemical features which separate them from other
GIST [32]. This class of GIST shows a female predominance and lymph node metastases are common, but the clinical course is usually indolent. The tumors arise in the stomach, are commonly multifocal and demonstrate a multi-nodular, lobulated growth pattern composed of predominantly epithelioid cells (▶ Fig. 3) [25]. SDH-deficient GIST are always negative for SDHB and strongly positive for both KIT and DOG1 by immunohistochemistry [32, 33]. Genetically, about 30% of SDH-deficient GIST are associated with SDHA mutations, which can be identified by loss of immunohistochemical SDHA protein expression (▶ Fig. 4) [34]. Up to 20% of tumors are associated with SDHB, SDHC or SDHD mutations and the remaining 50% harbors epigenetic hypermethylation of the SDHC promoter [25]. Mutations in SDHB, SDHC, and SDHD can also give rise to Carney–Stratakis syndrome, the familial dyad of PGL and GIST [35, 36]. The non-familial Carney triad is associated with SDH-deficient GIST, PGL and pulmonary chondromas and shows hypermethylation of the SDHC promoter [36, 37].

SDH-deficient RCC is currently being recognized as a distinct type of RCC in the WHO 2016 classification [25]. This class of RCC has a low risk of metastasis and demonstrates characteristic morphological features: 1) cystic change is common; 2) the tumor cells display eosinophilic cytoplasm with typical cytoplasmic vacuoles or inclusions, but lack the cytoplasmic granularity of oncocyttes; 3) the nuclei are homogeneous with a neuroendocrine appearance; 4) non-neoplastic tubules or glomeruli are frequently entrapped at the periphery of the tumor (▶ Fig. 3). Mast cells can be identified in the intratumoral stroma [38]. Most reported SDH-deficient RCC have been associated with SDHB mutation carriers, in which the risk of RCC by age 60 years is 4.7% [27]. However, RCC can occur in SDHC and SDHD mutation carriers as well, and one case of SDHA-deficient RCC has been described [39, 40].

SDH-deficient pituitary adenomas are very rare and to date, about 25 cases have been described in association with SDHA, SDHB, SDHC, and SDHD mutations [41]. These tumors are most often prolactin-producing or, to a lesser extent growth hormone-producing macroadenomas, but no distinct morphologic features have been reported [25, 41].
MYC-Associated Factor X

MYC-associated factor X (MAX) mutations were found to be a cause of hereditary PCC in 2011 [42]. A later study identified somatic MAX mutations, in addition to germline MAX mutations [43]. Patients with MAX mutations presented with bilateral and multiple PCC within the same adrenal gland.

MAX germline mutations have also been described in renal tumors. One case with a large genomic alteration in MAX was found in a patient with renal oncocytoma, erythrocytosis and bilateral PCC [44]. Initial data suggest that pathogenic variants in MAX exhibit parent-of-origin effects similar to those of pathogenic variants in SDHD where disease only becomes apparent when the pathogenic variant is inherited from the father.

Besides the multiple ipsilateral tumors there are no particular histologic characteristics described for MAX-mutated PCC and PGL. Immunohistochemical detection of MAX in tumor-embedded paraffin slides showed complete loss of the protein in all analyzed tumors that carried truncating mutations. Positive immunohistochemical staining was observed in all non-truncating variants. Some of these genetic variants were considered variants of unknown significance (VUS) [43]. Others have described that many PCC/PGL not associated with MAX mutations also demonstrate loss of MAX expression by immunohistochemistry, and that several PCC/PGL associated with MAX mutations do not demonstrate MAX loss by immunohistochemistry [45]. Therefore, MAX immunohistochemistry needs to be studied in larger series than hitherto performed.

Fumarate Hydratase

Fumarate hydratase (FH) is encoded by the FH gene on chromosome 1q42.1. Inactivation of this tricarboxylic acid cycle enzyme leads to abnormal cellular activation of the hypoxic gene response pathway and DNA methylation. Classically, FH mutations are associated with hereditary cutaneous and uterine leiomyomatosis and RCC [46]. In 2013, five patients with PCC/PGL were identified carrying FH mutations. Three of these five patients had metastatic PCC/PGL [47, 48]. In addition a FH germline mutation was found in a pediatric PCC [49]. No particular histologic characteristics have been described. However, the accumulation of FH in these tumors leads to protein succinate, which can be revealed by 2SC immunostaining. In addition, the accumulation of fumarate causes an inhibition of DNA methylases of the TET family involved in the hydroxylation of 5-methylcytosine to generate 5-hmC. FH-deficient tumors show (similar to SDHB-deficient tumors) an altered immunostaining pattern for 5-hmC. Immunohistochemical staining for 5-hmC is strongly positive in RET- and NF1-mutated tumors, and is negative in SDHB- and FH-mutated tumors (with positive internal control of endothelial cells) [48]. In addition to distinct loss of 5-hmC in tumor cells in SDHx- and FH-deficient tumors, it has been shown that FH-deficient smooth muscle tumors exhibit increased H3K9me3 methylation compared to wildtype tumors [50]. FH immunohistochemistry using the same criteria as for interpretation of SDHB immunohistochemistry can be used. One group has identified several germline FH-mutated PCC and one somatic FH-mutated PCC with loss of expression of FH by immunohistochemistry [45].

Transmembrane Protein 127

The TMEM127 tumor suppressor gene encodes a transmembrane protein that functions as a negative regulator of the mTOR pathway. Germline mutations in this gene were found in familial and sporadic PCC and a few cases have been described harboring PGL [51, 52]. The prevalence of PCC seems low (2–4 %). Clinically, patients are characterized by frequent bilateral PCC and a relatively high mean age at diagnosis compared to other syndromic PCC/PGL. The mean age at development of TMEM127-mutated tumors is 42.8 years and the median is 41.5 years. This age at onset is similar to the age of non-mutated cases (mean 43.2 years and median 45 years). This is in contrast with patients with hereditary PCC due to mutations in other susceptibility genes, in whom the disease has an earlier manifestation [53]. Metastases are detected in only a few cases, and no somatic TMEM127 mutations have yet been described. There are no particular histologic characteristics.

Prolyl Hydroxylase 1 and 2

Prolyl hydroxylase domain (PHD) proteins are involved in the degradation of HIF by hydroxylation. There are three main isoforms: PHD1, PHD2, and PHD3. Mutations in PHD2 have been implicated in the pathogenesis of polycythemia. However, recently germline PHD1 and PHD2 mutations have been described in patients with multiple PCC/PGL and polycythemia [54, 55]. Immunohistochemical expression of PHD1 and PHD2 proteins in tumors with PHD1 and PHD2 mutations was compared to normal adrenal medulla and to a sporadic non-PHD1/2-mutated PCC. The PHD1-related tumor showed negative staining for PHD1, while the expression of PHD2 was heterogeneous, with areas of negative staining (0) and areas with weak (1+) staining. PHD1 expression in the PHD2-mutated tumor was scored 1–2+; PHD2 staining in this sample was weak (1+). In the sporadic PCC, PHD1 staining exhibited intermediate/strong (2–3+) intensity and PHD2 staining was scored 1–2+. Human adrenal medulla shows strong (3+) staining for PHD1 and intermediate (2+) staining for PHD2 [55]. Although it appears that there might be a role for PHD1 and PHD2 immunohistochemistry in selected cases, this may not be practical given the small number of cases that has been described so far, both with regard to PHD mutations, and with regard to immunohistochemistry.

Hypoxia Inducible Factor 2 Alpha

HIF2alpha, encoded by EPAS1/HIF2A located on chromosome 2p21, is a transcription factor that responds to oxygen concentrations in tissue. It is a subunit of a heterodimer of which the other component is aryl hydrocarbon receptor nuclear translocator 2 (ARNT2/HIF2B). Under hypoxic conditions HIF stabilizes, thereby activating the hypoxia signaling pathway leading to angiogenesis, erythropoiesis, and cell growth [56]. In 2012, somatic HIF2A mutations were described in two patients with polycythemia and multiple PGL. One of these patients had a duodenal somatostatinoma [57]. Favier et al. found a heterozygous mutation in a PCC which affected the prolyl hydroxylase target residue of HIF2A. Gene expression data showed increased expression of hypoxia inducible genes. However, the effect was milder than seen in tumors with mutations in SDHx or VHL. In 2013,
four additional unrelated patients with somatic HIF2A mutations with multiple PGL, somatostatinomas and polycythemia were described, indicating a new syndrome [59]. In addition, germline mutations have been identified [60, 61]. It is now known that HIF2A mutations are identified in a variety of phenotypes, including polycythemia without tumors, polycythemia with single or multiple PCC/PGL, with and without somatostatinomas [56, 57, 60-63]. In addition, single or multiple PCC and PGL without polycythemia may occur [64, 65]. The fact that somatic mutations were found in patients with multiple PGL, somatostatinomas and polycythemia suggests the occurrence of a de novo postzygotic HIF2A mutation. In one patient it was shown that a heterozygous HIF2A mutation was present in the PGL, and that this mutation was also present as a mosaic in leukocyte DNA [66].

No specific macroscopic appearance or histologic features have been described for the PCC/PGL. In one study, immunohistochemistry for HIF1alpha and HIF2alpha was performed on the somatostatinoma and PGL of one HIF2A-mutated patient. Tumor cells showed nuclear staining for HIF2alpha in contrast to HIF1alpha where there was no nuclear staining [59]. Given the low number of cases, further analysis is needed to find out if there is a role for HIF1alpha and HIF2alpha immunohistochemistry in the detection of specific subgroups of PCC.

Kinesin Family Member 1B
The Kinesin Family member 1B (KIF1B) gene is located on chromosome 1p36.22 and encodes for protein kinesin family member 1B. There are two isoforms, KIF1Balpha and KIF1Bbeta. These proteins are responsible for transport of materials via microtubules within cells and are abundantly expressed in differentiated nerve cells [67]. Studies suggest that deletion or mutation of the KIF1B gene may disrupt apoptosis, which leads to tumorigenesis. KIF1B mutations have been described in neuroblastomas and in Charcot-Marie-Tooth disease type 2A peripheral neuropathy [68, 69]. In 2008 the first PCC cases with KIF1B germline mutations were published. In this study, all 46 exons of KIF1Bbeta were sequenced and a missense variant was found in 2/52 PCC [70]. Evenepoel et al. sequenced 74 tumors (47 PCC and 27 PGL) and identified somatic mutations in 54% of patients. In this study, the most frequently somatically mutated genes in PCC were NF1 (20.8%) and KIF1B (20.4%). No significant difference in the proportion of KIF1B mutations was observed between PCC and PGL (46% vs. 30%) [71]. Yeh et al. described germline KIF1Bbeta mutations in a family with neural and non-neural tumors. One female patient presented at 17 months of age with a neuroblastoma and developed a ganglioneuroma and bilateral PCC. Her paternal grandfather also developed bilateral PCC, which showed few areas of necrosis, diffuse architecture and hyaline globules, narrowed cord pattern, anisokaryosis and intense adjacent medullary hyperplasia [70, 72]. The patient’s PCC also showed narrowed cord pattern, hyaline globules and in some areas atypia/anisokaryotic cells. In addition, an intracapillary tumor embolus was present. FISH analysis of the tumors showed two signals for KIF1Bbeta and no LOH was identified by SNP array. These findings deviate from the classic two-hit tumor suppressor gene model.

Multiple Endocrine Neoplasia Type 1
Multiple endocrine neoplasia type 1 (MEN1) is characterized by tumors of the parathyroid, pancreas and pituitary. In addition, some patients may develop bronchial carcinoids, facial angiofibromas, and adrenal cortical tumors. MEN1 is a tumor suppressor gene located on chromosome 11q13.1 and encodes for the protein menin. This protein is present in the nucleus of many different types of cells and interacts with transcription factor JunD [73]. No clear genotype-phenotype correlation is present. Adrenal involvement in MEN1 is about 20% and almost exclusively concerns adrenal cortical lesions [74]. PCC in MEN1 are rare; only a few cases have been described [75]. Most tumors are unilateral and metastasis has only been described in one patient [76]. Okada et al. described an MEN1-patient with a giant insulinoma of the pancreatic tail, concomitant PCC and an adrenal cortical adenoma in the same adrenal gland [77]. The combination of pituitary adenomas and PCC is rare and this has been associated with mutations in SDHA, SDHB, and SDHD [78, 79]. Only four cases of co-existing PCC/PGL and pituitary adenoma have been reported in patients with MEN1. In one of these PCC absent menin staining was demonstrated [80]. In cell lines tested, menin was found both in the nucleus and in the cytoplasm, but its localization was dependent on the phase of the cell cycle; during a non-dividing phase, menin was found in the nucleus; during and immediately after cell division, it was found in the cytoplasm [81]. Tissue from MEN1-associated primary hyperparathyroidism was evaluated by immunohistochemistry. Lack of nuclear menin was identified in all MEN1-associated parathyroid tissues. The sensitivity and specificity of menin immunohistochemistry to detect a MEN1 mutation in this study were 86% and 87%, respectively [82]. To the best of our knowledge, no results of menin immunohistochemistry on PCC/PGL have been reported.

Recently Identified PCC/PGL Genes
Malate dehydrogenase 2 (MDH2) was identified as a familial PGL gene by whole-exome sequencing in a male patient with multiple retroperitoneal and thoracic PGL. MDH2 encodes another Krebs cycle enzyme, and malfunction results in a severe energy deficit and accumulation of malate and fumarate. A similar mechanism occurs in Fh1-deficient cells that accumulate fumarate (see above). Immunohistochemical staining of 5-hmC was undetectable in MDH2- and SDHB-mutated tumor cells, and was observed only in sustentacular and some stromal cells [83]. Very recently, it was shown that MDH2 might play a role in less than 1% of PCC and PGL that do not show mutations in other driver genes [84].

Targeted exome sequencing identified a germline glutamic-oxaloacetic transaminase 2 (GOT2) variant (c.357A>T) in a patient with metastatic thoracic-abdominal PGL. GOT2 is a mitochondrial enzyme involved in amino acid metabolism and both the urea and Krebs cycle. In GOT2 -mutated (c.357A>T) tumor cells increased GOT2 expression and enzymatic activity was found, as well as a high succinate/fumarate ratio. GOT2 immunohistochemistry on two tumors of the patient showed cytoplasmic aggregates, while this was not observed in a control (non-GOT2 mutated) tumor [85]. In addition, a truncating germline IDH3B mutation was found in a 51-year-old patient with a jugular PGL. The beta subunit of isoc-
It is involved in the oxidation of isocitrate to α-ketoglutarate in the Krebs cycle. The IDH3B-mutated PGL showed negative 5-hmC immunohistochemical staining, which is also found in SDH- and FH-mutated tumors [84].

A germline mutation in the SLC25A11 gene, which encodes the mitochondrial 2-oxoglutarate/malate carrier (OGC) was identified by whole-exome sequencing in an abdominal PGL in a 46-year-old male patient. In addition, six patients with germline SLC25A11 mutations were identified by Sanger sequencing in a large cohort of 639 patients (five patients with a single metastatic abdominal PGL and one with a head and neck PGL). SLC25A11 gene mutations account for 1% of all PCC/PGL and confer a predisposition to metastatic tumors. No OGC protein was observed in the PGL carrying the SLC25A11 mutation. Moreover, 5-hmC immunohistochemistry was negative in all but one SLC25A11-mutated tumor, whereas H3K9me3 and H3K27me3 stainings were positive in all cases [86].

A novel germline mutation in the DNA-methyltransferase 3 alpha (DNMT3A) gene was identified in a 23-year-old female patient with multiple PGL (larynx, carotid, jugulotympanic, juxtavagal, and mediastinum). De novo DNA methyltransferases, DNMT3A and DNMT3B, establish DNA methylation patterns during embryonic development. A second germline DNMT3A mutation was identified in a 54-year-old

---

**Table 1** Genes and tumor associations of pheochromocytoma (PCC) and paraganglioma (PGL).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Site</th>
<th>PCC/PGL incidence</th>
<th>Other tumors</th>
<th>Clues for diagnosis</th>
<th>IHC PCC/PGL</th>
</tr>
</thead>
<tbody>
<tr>
<td>RET</td>
<td>PCC × PGL</td>
<td>40–50%</td>
<td>MTC, parathyroid tumor, mucosal ganglioneuroma</td>
<td>Multiple and bilateral tumors, AMH</td>
<td></td>
</tr>
<tr>
<td>VHL</td>
<td>PCC × PGL</td>
<td>10–26%</td>
<td>Clear cell RCC, hemangioblastoma, retinal angioma, pancreatic serous cystadenoma</td>
<td>Multifocal and bilateral tumors, thick vascular tumor capsule</td>
<td>CAIX + (?)</td>
</tr>
<tr>
<td>NF1</td>
<td>PCC × PGL</td>
<td>&lt;6%</td>
<td>Neurofibroma, ganglioneuroma, MPNST, schwannoma, optic nerve glioma, GiST</td>
<td>Compostie PCC intermixed with ganglioneurublastoma/ganglioneuroma</td>
<td></td>
</tr>
<tr>
<td>SDHA</td>
<td>PGL &gt; PCC</td>
<td>Rare</td>
<td>SDH-def. GIST and RCC, PA</td>
<td>SDHB – , SDHA –</td>
<td></td>
</tr>
<tr>
<td>SDHB</td>
<td>EA PGL + H &amp; N PGL &gt; PCC</td>
<td>25–40%</td>
<td>SDH-def. GIST and RCC, PA</td>
<td>SDHB – , SDHA +</td>
<td></td>
</tr>
<tr>
<td>SDHC</td>
<td>H &amp; N PGL &gt; EA PGL/PCC</td>
<td>Rare</td>
<td>SDH-def. GIST and RCC, PA</td>
<td>SDHB – , SDHA +</td>
<td></td>
</tr>
<tr>
<td>SDHD</td>
<td>H &amp; N PGL &gt; EA PGL/PCC</td>
<td>86%</td>
<td>SDH-def. GIST and RCC, PA</td>
<td>SDHB – , SDHA +</td>
<td></td>
</tr>
<tr>
<td>SDHAF2</td>
<td>H &amp; N PGL</td>
<td>Very rare</td>
<td>Not reported</td>
<td>SDHB – , SDHA +</td>
<td></td>
</tr>
<tr>
<td>MAX</td>
<td>PCC × PGL</td>
<td>Rare</td>
<td>Renal tumors, neuroblastoma</td>
<td>Multiple and bilateral tumors, AMH</td>
<td></td>
</tr>
<tr>
<td>FH</td>
<td>PCC and PGL</td>
<td>Rare</td>
<td>RCC, leiomyoma</td>
<td>2SC + , 5-hmC –</td>
<td></td>
</tr>
<tr>
<td>TMEM127</td>
<td>PCC × PGL</td>
<td>&lt;20%</td>
<td>Not reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHD1/2</td>
<td>PCC and PGL</td>
<td>Rare</td>
<td>Not reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIF2A</td>
<td>PGL &gt; PCC</td>
<td>Rare</td>
<td>Somatostatinoma</td>
<td>HIF2a + , HIF1a – (?)</td>
<td></td>
</tr>
<tr>
<td>KIF1B</td>
<td>PCC</td>
<td>Rare</td>
<td>Ganglioneuroma, leiomyosarcoma, neuroblastoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEN1</td>
<td>PCC × PGL</td>
<td>Very rare</td>
<td>Parathyroid tumors, enteropancreatic NET, PA, thymus or bronchial carcinoid,</td>
<td>Menin – in MEN1-associated parathyroid tissue</td>
<td></td>
</tr>
<tr>
<td>MDH2</td>
<td>PGL</td>
<td>Very rare</td>
<td>Neuroblastoma</td>
<td>5-hmC –</td>
<td></td>
</tr>
<tr>
<td>GOT2</td>
<td>PGL</td>
<td>Very rare</td>
<td>Neuroblastoma</td>
<td>5-hmC –</td>
<td></td>
</tr>
<tr>
<td>IDH3B</td>
<td>H &amp; N PGL</td>
<td>Very rare</td>
<td>AML</td>
<td>5-hmC – , H3K9me3 + , H3K27me3 + , OGC –</td>
<td></td>
</tr>
<tr>
<td>SLC25A11</td>
<td>PGL</td>
<td>1%</td>
<td>AML</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNMT3A</td>
<td>H &amp; N PGL</td>
<td>Very rare</td>
<td>AML</td>
<td>H3K9me3 +</td>
<td></td>
</tr>
</tbody>
</table>

IHC: Immunohistochemistry; EA: Extra-adrenal; H & N: Head and neck; MTC: Medullary thyroid carcinoma; RCC: Renal cell carcinoma; MPNST: Malignant peripheral nerve sheath tumor; GIST: Gastrointestinal stromal tumor; PA: Pituitary adenoma; SDH-def.: Succinate dehydrogenase-deficient; NET: Neuroendocrine tumor; AMH: Adrenal medullary hyperplasia; AML: Acute myelogenous leukemia; + : Positive staining; –: Negative staining.
female with two head and neck PGL, of whom the mother also was diagnosed with bilateral head and neck PGL. DNMT3A-mutated PGL showed strong immunostaining of H3K9me3 [87].

An overview of PCC/PGL susceptibility genes and tumor associations, including clues for diagnosis and immunohistochemical markers is depicted in Table 1.

Conclusions

PCC have been associated with a large number of genes that may be mutated in the germline or somatically. In this review, we have concentrated on genes that are associated with PCC (and not with PGL only) and on those that have been described at sufficient frequency of occurrence and/or for which data on the relationship between gross, microscopic and immunohistochemical details on the one hand and genetic background on the other hand were available.

It should be concluded that important clues can be gathered from the attentive study of adrenalectomy specimens and the corresponding microscopy. Specifically, the presence of bilateral disease and/or multiple nodules should raise suspicion for hereditary disease, most notably MEN2 syndrome. If tumors are particularly hemorrhagic and vascular, a diagnosis of VHL disease could be entertained. Composite histology between PCC and a neuroblastic tumor has most often been described in the context of NF1 gene abnormalities.

With regard to immunohistochemistry, the use of SDHA and SDHB immunohistochemistry should be regarded as standard for specialized centers, allowing to direct genetic testing to the group of SDH genes or away from it (if there is a normal pattern of SDHB immunostaining). Although much less frequent and therefore much less reported, immunohistochemistry for MAX and for 2-SC immunostaining). Although much less frequent and therefore much less reported, immunohistochemistry for MAX and for 2-SC

It should be noted that with the advent of targeted sequencing using NGS panels, and even more when using whole exome or whole genome sequencing, all PCC (and PGL) susceptibility genes can be analyzed at the same time. Therefore, stepwise analysis on the basis of clinical or pathological clues will most likely become obsolete. However, immunohistochemistry will continue to have an important ancillary role in the analysis of genetic variants of unknown significance.

Conflict of Interest

The authors declare that they have no conflict of interest.

References


[31] Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumors and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome); molecular genetics and clinical implications. J Intern Med 2009; 266: 43–52


Oudjik L et al. PCC Histology and Genetics... Horm Metab Res 2019; 51: 403–413


